DE   EN   ES   FR   IT   PT Medicines Antiemetic — dopamine receptors the antagonist central. Motilak


Препарат Мотилак. ОАО "ВЕРОФАРМ" Россия


Producer: JSC VEROPHARM Russia

Code of automatic telephone exchange: A03FA03

Release form: Firm dosage forms. Tablets.

Indications to use: Dyspepsia. Esophagitis. Meteorism. Nausea. Vomiting.

General characteristics. Structure:

Motilak - the tablets covered obolochkoy:1 with the tab. contains домперидон 10 mg; excipients: potato starch; lactose; MKTs; aerosil; polyvinylpirrolidone; magnesium stearate; sodium carboxymethylstarch; oksipropiltsellyuloza; twin-80; titanium dioxide; silicon dioxide colloid; in packaging of 10 and 30 pieces; Motilak - tablets for rassasyvaniya:1 the tab. contains домперидон 10 mg; in packaging of 10 and 30 pieces.

Pharmacological properties:

Pharmacodynamics. Increases duration of peristaltic reductions of antral department of a stomach and duodenum, accelerates gastric emptying in case of delay of this process, raises a tone of the lower esophageal sphincter, eliminates development of nausea and vomiting. Domperidon badly gets through a blood-brain barrier therefore use of a domperidon seldom is followed by extrapyramidal side effects, especially at adults, but домперидон stimulates release of prolactin from a hypophysis. Its antiemetic action, perhaps, is caused by a combination of peripheral (gastrokinetichesky) action and antagonism to dopamine receptors in a trigger zone of chemoceptors. Domperidon has no effect on gastric secretion.


Absorption. After administration of drug inside домперидон it is quickly soaked up. Has low bioavailability (about 15%). The lowered acidity of gastric contents reduces absorption of a domperidon. The maximum concentration in plasma is reached in 1 h.

Distribution. Domperidon is widely distributed in various fabrics, in brain tissues its concentration is small. Linkng with proteins of plasma makes 91–93%. Metabolism Is exposed to intensive metabolism in a wall of intestines and liver.

Removal. It is removed through intestines (66%) and kidneys (33%), in not changed look 10% and 1% of dose size are removed, respectively. The elimination half-life makes 7–9 h, at the expressed renal failure it is extended.

Indications to use:

The complex of dispepsichesky symptoms which is often associated with the slowed-down gastric emptying, a gastroesophagal reflux, an esophagitis; feeling of overflow in epigastriums, feeling of abdominal distention, pain in an upper part of a stomach; eructation, meteorism; heartburn with throwing or without throwing of contents of a stomach in an oral cavity. The nausea and vomiting of a functional, organic, infectious origin caused by radiotheraphy, medicinal therapy or disturbance of a diet and also against the background of dopamine agonists in case of their use at Parkinson's disease (such as L-dopa and Bromocriptinum).

Route of administration and doses:

Chronic dyspepsia Adults: on 10 mg (1 tablet) 3 times a day, in 15–30 min. prior to food and , in case of need, before going to bed. Children are more senior than 5 years: on 2,5 mg on 10 kg of body weight 3 times a day to food and , in case of need, before going to bed. If necessary the specified dosage can be doubled. Acute and subacute states (first of all nausea and vomiting) Adults: on 20 mg (2 tablets) 3–4 times a day, to food and before going to bed. Children are more senior than 5 years: on 5 mg on 10 kg of body weight, 3–4 times a day before food and before going to bed. Notes oral administration of Motilak to food Is recommended. At administration of drug after food absorption is a little slowed down. At a renal failure reduction of frequency of administration of drug is recommended (see the section "Special Instructions").

Features of use:

At the combined use of Motilak with antiacid or anti-secretory drugs the last should be applied after food, but not to food, t.   е. they  should not be accepted along with Motilak

Side effects:

Side effects are observed seldom, exceptional cases of passing enterospasms were celebrated. The extrapyramidal phenomena are observed at children and at a hyperpermeability of a blood-brain barrier. These phenomena are completely reversible and spontaneously disappear after the treatment termination. As the hypophysis is out of a blood-brain barrier, Motilak can induce increase in level of prolactin in plasma. In rare instances this giperprolaktinemiya can stimulate emergence of a galactorrhoea, gynecomastia and dysmenorrhea. Rare allergic reactions such as rash and urticaria were noted.

Interaction with other medicines:

Motilak does not break speed of reaction. Medicinal interactions At simultaneous use anticholinergic drugs can neutralize Motilak's action. At simultaneous use with Motilak antiacid and anti-secretory drugs reduce its bioavailability. On the basis of the researches in vitro it is possible to assume that at simultaneous use with Motilak of the medicines considerably inhibiting enzyme CYP3A4 cytochrome (antifungal drugs of group of azoles, antibiotics from group of macroleads, HIV protease inhibitors, antidepressant нефазодон) increase in level of a domperidon in plasma can be observed. Domperidon does not influence the level of paracetamol and digoxin in blood. It is not excluded that Motilak can influence absorption applied at the same time in drugs with the slowed-down release of active agent or covered with a kishechnorastvorimy cover.


The established intolerance of drug, prolactin - the cosecreting tumor of a hypophysis (prolaktinom), children's age up to 5 years.

 It is not necessary to apply Motilak when stimulation of motive function of a stomach can be dangerous, t.   е. at gastrointestinal bleeding, mechanical impassability or perforation.

Use at liver diseases. Considering metabolism of a domperidon in a liver, it is necessary to appoint with care Motilak sick with a liver failure. Use at diseases of kidneys For patients with a heavy renal failure (serumal creatinine> of 6 mg / 100 ml, t.   е.> 0,6 mmol/l) the elimination half-life of a domperidon increased  from 7,4 to 20,8 o'clock, but concentration of drug in plasma were lower, than at healthy volunteers. As very small percent of drug is removed by kidneys in not changed look,  correction of a single dose at patients with a renal failure is hardly necessary. However at repeated appointment the frequency of introduction has to be reduced to 1–2 times a day, depending on weight of insufficiency, there can also be a need of dose declines. At long therapy patients have to be under regular observation.

Use during pregnancy and a lactation. At introduction by an animal in doses to 160 mg/kg/days домперидон had no teratogenic effect. However, as the majority of medicines, Motilak it is necessary to appoint during the first trimester of pregnancy only if its use is justified by the expected therapeutic advantage. So far   people do not have data on increase in risk of malformations. At women of concentration of a domperidon in breast milk is 4 times lower, than the corresponding concentration in plasma. It is unknown whether this level makes negative impact on newborns. Therefore if mother is accepted by Motilak, feeding by a breast is not recommended, except for cases when the expected advantage justifies potential risk.


Symptoms: drowsiness, a disorientation and extrapyramidal reactions, especially at children. Treatment: in case of overdose use of absorbent carbon and careful observation is recommended. Anticholinergics, the drugs used for treatment of parkinsonism or antihistaminic drugs can be effective at emergence of extrapyramidal reactions.

Storage conditions:

Period of validity 2 years. Not to apply after the term specified on packaging. In the dry, protected from light place, at a temperature not above 25 °C.

Issue conditions:

Without recipe


10 tablets in the blister. On 1 or 3 blisters in a cardboard pack with the application instruction, 30 tablets in bank of orange glass in a cardboard pack with  the application instruction.

Similar drugs

Препарат Домрид таблетки. ОАО "ВЕРОФАРМ" Россия

Domrid of a tablet

Vermicular movement stimulators (propulsant).

Препарат Мотиллион. ОАО "ВЕРОФАРМ" Россия


Antiemetic. Stimulator of motility of digestive tract.

Препарат Домрид суспензия. ОАО "ВЕРОФАРМ" Россия

Domrid suspension

Vermicular movement stimulators (propulsant).

Препарат Пассажикс. ОАО "ВЕРОФАРМ" Россия


Antiemetic — dopamine receptors a blocker central.

Препарат Домидон. ОАО "ВЕРОФАРМ" Россия


Vermicular movement stimulators (propulsant).

Препарат Домрид SR. ОАО "ВЕРОФАРМ" Россия

Domrid SR

Vermicular movement stimulators (propulsant).

Препарат Лимзер. ОАО "ВЕРОФАРМ" Россия


Antiulcerous drugs. Blockers histamine H2 receptors.

Препарат Домперидон -Тева. ОАО "ВЕРОФАРМ" Россия

Domperidon - Teva

Antiemetic - dopamine receptors a blocker central.


Vermicular movement stimulators (propulsant).

Препарат Мотилак. ОАО "ВЕРОФАРМ" Россия


Antiemetic — dopamine receptors a blocker central.

Препарат Домперидон. ОАО "ВЕРОФАРМ" Россия


Antiemetic - dopamine receptors a blocker central.

Препарат Домстал. ОАО "ВЕРОФАРМ" Россия


Antiemetic — dopamine receptors the antagonist central.

Препарат Мотилак. ОАО "ВЕРОФАРМ" Россия



Препарат Домперидон. ОАО "ВЕРОФАРМ" Россия



  • Сайт детского здоровья